Ischaemic heart disease: association with haematocrit in the British Regional Heart Study

Goya Wannamethee, A G Shaper, P H Whincup

Abstract
Objectives — To assess the relationship between haematocrit and risk of major ischaemic heart disease events.
Design — Prospective study of a cohort of men followed up for 9-5 years.
Setting — General practices in 24 towns in England, Wales, and Scotland (British Regional Heart Study).
Subjects — Altogether 7735 men aged 40–59 years at screening, who were selected at random from one general practice in each of 24 towns, were studied.

Main outcome measures — Fatal and non-fatal ischaemic heart disease events.

Results — Risk of major ischaemic heart disease events was significantly increased at haematocrit levels of ≥46%. Men with raised haematocrit (≥46%) showed a 30% increase in relative risk (RR) of major ischaemic heart disease events (RR=1.32; 95% confidence intervals (CI) 1.10,1.57, p<0.01) compared with those with values below 46%, even after adjustment for age, social class, smoking, body mass index, physical activity, blood cholesterol, lung function (FEV1), and pre-existing evidence of ischaemic heart disease. Further adjustment for systolic blood pressure reduced the risk slightly (RR=1.27; 95% CI 1.06,1.51, p=0.02) but it remained significant. The relationship was seen in men with and without pre-existing evidence of ischaemic heart disease. The study suggests that an increased haematocrit level plays a part in the development of major ischaemic heart disease events.

(J Epidemiol Community Health 1994;48:112–118)

Patients with polycythaemia rubra vera who have a noticeably raised haematocrit level experience an increased risk of ischaemic heart disease (IHD).1 This may be a consequence of the influence of haematocrit on blood viscosity.2 Recent evidence also suggests that the plasma component of viscosity may play a role in the development of atherosclerosis.4 However, population studies examining the relationship between haematocrit or haemoglobin and major IHD events have been inconclusive. Most studies have reported a positive association between haematocrit or haemoglobin (which are highly correlated) and the risk of heart attacks,5–12 and some of these have found the association to be independent of the coronary risk factors.6–8 Other studies have found the relationship to be dependent on established cardiovascular risk factors, for example smoking, blood pressure, and blood cholesterol,10–12 and others have reported no association.13–14 In most of these studies a linear relationship between haematocrit and outcome has been assumed. A recent study, however, has shown a significantly increased risk of heart attacks in subjects with levels above 46% compared with those with values below this, independent of the recognised risk factors.6 This suggests that the relationship may not be linear and that risk may be increased only above certain threshold levels of haematocrit. This study examines the relationship between haematocrit and risk of major IHD events in a large prospective study of middle-aged men, and focuses on the role of cardiovascular risk factors in the relationship between ischaemic heart disease and haematocrit.

SUBJECTS AND METHODS
The British Regional Heart Study is a large prospective study of cardiovascular disease comprising 7735 men aged 40–59 years selected from the age-sex registers of one group general practice in each of 24 towns in England, Wales, and Scotland. The criteria for selecting the town, the general practice, and the subjects as well as the methods of data collection, have been reported.15 Research nurses administered to each man a standard questionnaire that included questions on smoking habits, alcohol intake, physical activity, and medical history. Several physical measurements were made. Classification methods for smoking status, alcohol consumption, occupation (social class), and body mass index (BMI) have been reported.16 Obesity is defined as a BMI ≥28 kg/m2, the top 20% of the distribution in these men. The men were asked to indicate their usual pattern of physical activity, under the headings of regular walking or cycling, recreational (weekend) activity, and active physical exercise. A physical activity (exercise) score was derived for each man based on the frequency and type (intensity) of the physical activity. Full details of the derivation of the score have been described.16 The men were grouped into six broad categories based on their total score: inactive, occasional, light, moderate, moderately-vigorous, and vigorous. Those engaged in at least moderate levels of physical activity were classified as active.

HAEMATOCRIT
Blood samples (non-fasting) were taken for measurement of biochemical and haematologi-
cal variables. All samples reached the Department of Haematology, Queen Elizabeth Hospital, Birmingham by the following morning and estimations were completed by noon of that day. Haematocrit was estimated using a Coulter S electronic particle counter (Coulter Electronics Ltd, Luton) calibrated daily with Coulter SC. Internal quality control was achieved using an algorithm based on patient-derived haematology data, modified from Bull et al., and external quality assurance by participation in the National External Quality Assurance Scheme (NEQAS).

Haematocrit and haemoglobin concentration were strongly correlated \( (r = 0.93) \) and only the haematocrit findings are presented in this paper. The men were divided into five groups based on levels of haematocrit: 

- \( <42.0\% = 1218 \text{ men} \)
- \( 42.0-43.9\% = 1648 \text{ men} \)
- \( 44.0-45.9\% = 2018 \text{ men} \)
- \( 46.0-47.9\% = 1414 \text{ men} \)
- \( \geq 48.0\% = 1048 \text{ men} \)

**SERUM PROTEIN**

Thirteen biochemical factors, including albumin and globulin, were measured on serum with a Technicon SMA 12/60 "Autoanalyzer". Total serum protein was defined as albumin + globulin concentrations. No measurement of fibrinogen was available.

**BLOOD PRESSURE**

The men attended the examination centre over a 10 hour period between 8.30 am and 6.30 pm on weekdays and were not asked to fast or to abstain from alcohol beforehand. The London School of Hygiene sphygmomanometer was used to measure blood pressure twice in succession, using a standard adult cuff on the right arm of all subjects and with the subjects seated and the arm supported on a cushion. The mean of the two readings was used in the analysis and all blood pressure readings were adjusted for observer variation within each town.

**PRE-EXISTING IHD**

The men were asked whether a doctor had ever told them that they had angina or myocardial infarction (heart attack, coronary thrombosis), stroke, and a number of other disorders. The WHO (Rose) chest pain questionnaire was administered to all men at the initial examination\(^{16} \) and a three-orthogonal lead electrocardiogram was recorded at rest and analysed by computer in the Department of Medical Cardiology, Glasgow Royal Infirmary. Men with evidence of IHD were defined as those with a recall of doctor diagnosis of angina or heart attack, WHO (Rose) questionnaire responses indicating angina (definite or possible) or possible myocardial infarction, or electrocardiographic evidence of definite or possible myocardial ischaemia or myocardial infarction. Definite myocardial infarction is defined as men with recall of a doctor diagnosis of a myocardial infarction or evidence of definite myocardial infarction on electrocardiogram.

**FOLLOW UP**

All men have been followed up for all cause mortality and for cardiovascular morbidity for 9-5 years.\(^{20} \) Information on death was collected through the established "tagging" procedures provided by the National Health Service registers in Southport (England and Wales) and Edinburgh (Scotland). Fatal IHD events included all deaths with ischaemic heart disease as the underlying cause (International Classification of Disease, 9th revision, codes 410-414) which occurred during the period of follow up, irrespective of non-fatal events which may have preceded the fatal event during the follow up period. A non-fatal heart attack was one which satisfied at least two of the following WHO criteria: (a) preceded by severe prolonged chest pain, (b) electrocardiographic evidence of myocardial infarction, (c) cardiac enzyme changes associated with myocardial infarction.

**STATISTICAL METHODS**

Multiple logistic regression was used to obtain the relative risks for the five haematocrit groups adjusted for age, smoking, social class, physical activity, body mass index, lung function, pre-existing IHD, blood cholesterol, and systolic blood pressure. Age, body mass index, lung function, blood cholesterol, and systolic blood pressure were fitted as continuous variables, smoking as four dummy variables (never, ex-smokers, light, moderate, and heavy), and social class as two dummy variables (manual, non-manual, and Armed Forces). Haematocrit was fitted as four dummy variables for the five haematocrit groups and in some of the analyses as one dummy variable \((\geq 46\% \text{ vs the rest})\). Fitting haematocrit as five categorical groups makes no assumptions of a linear relationship between haematocrit and risk of major IHD events.

**Results**

Data on haematocrit were available on 7346 men with a mean (SD) of \( 44.47\% \pm 3.16\% \), range 25-63%. During the follow up period of 9-5 years in these 7346 men there were 580 major IHD events (non-fatal heart attacks and all IHD deaths including sudden cardiac death).

**HAEMATOCRIT AND RISK OF MAJOR IHD EVENTS**

Figure 1 shows the crude heart attack rate/1000/year by the five haematocrit groups in all men. There was little difference in risk of major IHD events in men with haematocrit levels below 46.0%. Risk was significantly increased at levels of 46.0% and above. A global test for overall difference between the five groups was significant \((p < 0.001)\).

**HAEMATOCRIT AND CORONARY RISK FACTORS**

Table 1 shows the relationship between the five haematocrit groups and factors associated
with the risk of major IHD events. There was no consistent association with age or with social class. Smoking, BMI, and obesity were strongly associated with haematocrit (p < 0.0001). Physical activity showed a small but significant inverse relationship (p < 0.0001). Forced expiratory volume in one second (FEV₁) decreased significantly with increasing haematocrit (p < 0.0001).

HAEMATOCRIT AND PRE-EXISTING DISEASE

Table 1 also shows the relationship between haematocrit and presence of pre-existing IHD and diabetes. The prevalence of pre-existing IHD and definite myocardial infarction increased significantly with increasing haematocrit. Diabetes was somewhat more prevalent in the lowest haematocrit group but there was no consistent relationship in the other groups.

<table>
<thead>
<tr>
<th>Haematocrit</th>
<th>Trend, p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (y)</td>
<td>50.7 50.0 50.1 50.1 50.7 NS</td>
</tr>
<tr>
<td>Manual work (%)</td>
<td>63 56 57 57 NS</td>
</tr>
<tr>
<td>Smoking:</td>
<td></td>
</tr>
<tr>
<td>Never (%)</td>
<td>30 27 24 20 14 ***</td>
</tr>
<tr>
<td>Ex-smoker (%)</td>
<td>40 40 37 33 25 ***</td>
</tr>
<tr>
<td>Current (%)</td>
<td>30 33 39 47 61***</td>
</tr>
<tr>
<td>Physical activity:</td>
<td></td>
</tr>
<tr>
<td>Inactive (%)</td>
<td>7.1 8.3 8.1 9.6 13.0 ***</td>
</tr>
<tr>
<td>Active (%)</td>
<td>39 41 35 36 23 **</td>
</tr>
<tr>
<td>Mean BMI</td>
<td>24.9 25.2 25.7 25.6 26.2 ***</td>
</tr>
<tr>
<td>Obese (%)</td>
<td>15 16 21 20 27 **</td>
</tr>
<tr>
<td>Mean FEV₁</td>
<td>341.1 340.1 335.2 330.5 313.1 ***</td>
</tr>
<tr>
<td>Pre-existing disease (%)</td>
<td></td>
</tr>
<tr>
<td>Definite myocardial infarction</td>
<td>5.3 3.6 5.6 6.9 7.4 **</td>
</tr>
<tr>
<td>Any ischaemic heart disease (%)</td>
<td>24 22 24 27 31 **</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>2 1 1.5 1.2 NS</td>
</tr>
<tr>
<td>Mean systolic blood pressure</td>
<td>141.4 143.5 145.2 147.0 149.8 NS ***</td>
</tr>
<tr>
<td>Mean diastolic blood pressure</td>
<td>78.3 80.8 82.5 84.2 86.3 NS ***</td>
</tr>
<tr>
<td>Mean cholesterol</td>
<td>6.01 6.25 6.32 6.42 6.54 NS ***</td>
</tr>
<tr>
<td>Mean triglyceride</td>
<td>1.52 1.67 1.73 1.82 2.01 ♥ ♥ ♥</td>
</tr>
<tr>
<td>Mean HDL cholesterol</td>
<td>1.16 1.17 1.15 1.15 1.15 NS</td>
</tr>
<tr>
<td>Mean glucose</td>
<td>5.52 5.47 5.47 5.47 5.52 NS</td>
</tr>
</tbody>
</table>

NS = non-significant; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; BMI = body mass index; FEV₁ = forced expiratory volume in one second.
addition to blood cholesterol. Since blood pressure may be a mediating factor between haematocrit and the risk of a major IHD event, we have further adjusted, first in addition for blood cholesterol (table 2, column D) and then in addition for systolic blood pressure (table 2, column E). Adjustment for blood cholesterol reduced the increased risk of ischaemic heart disease seen in those with raised haematocrit (≥46-0%), but the risk nevertheless increased significantly at levels of 46-0% or above. Adjustment for systolic blood pressure reduced the increased risk of major IHD events even further but a raised haematocrit (≥46-0%) was still associated with a significant increase in risk. Since those with haematocrit (<42-0%) had the lowest blood pressures and blood cholesterol concentrations, adjustment for these factors increased the risk slightly in these men.

TABLE 2 Haematocrit and adjusted relative risk (RR) (95% confidence interval) of major ischaemic heart disease (IHD) events

<table>
<thead>
<tr>
<th>Haematocrit level</th>
<th>No of men</th>
<th>No of IHD cases</th>
<th>Adjusted RRs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A</td>
</tr>
<tr>
<td>&lt;42</td>
<td>1218</td>
<td>82</td>
<td>1-06</td>
</tr>
<tr>
<td>42-144</td>
<td>1648</td>
<td>100</td>
<td>1-00</td>
</tr>
<tr>
<td>44-141</td>
<td>2018</td>
<td>139</td>
<td>1-15</td>
</tr>
<tr>
<td>46-144</td>
<td>1414</td>
<td>140</td>
<td>1-75</td>
</tr>
<tr>
<td>48-148</td>
<td>1048</td>
<td>119</td>
<td>1-92</td>
</tr>
</tbody>
</table>

Relative risk ≥46-0% v rest | 1-70 | 1-48 (1.23-1.77) | 1-40 (1.17-1.67) | 1-32 (1.10-1.57) | 1-27 (1.06-1.51) |

(A) Age adjusted.
(B) Adjusted for age, body mass index, social class, smoking, and physical activity.
(C) Adjusted for (B) and pre-existing ischaemic heart disease, diabetes, and forced expiratory volume in one second.
(D) Adjusted for (C) and in addition for blood cholesterol.
(E) Adjusted for (D) and in addition for systolic blood pressure.

Additional adjustment for blood cholesterol (column B) and systolic blood pressure (column C) reduced the excess risk slightly and increased slightly the risk seen in those with low haematocrit (<42-0%). In men with no pre-existing IHD, those with haematocrit levels ≥46-0% showed significantly higher risk than those with levels below even after these adjustments, although risk seemed to decline in those in the highest haematocrit group (≥48%). In those with pre-existing IHD, increased risk was present but not statistically significant.

POSSIBLE INTERACTIONS

We have also explored possible interactions between haematocrit, smoking, systolic blood pressure, and blood cholesterol with the risk of IHD. Figure 2 shows the adjusted relative risk of major IHD events in relation to the two haematocrit groups (≥46-0% and <46-0%) plotted on a log scale by smoking, systolic blood pressure, and blood cholesterol concentration. Within all smoking, systolic blood pressure, and blood cholesterol categories, raised haematocrit (≥46-0%) showed higher risk than those with levels below 46-0% (figure 2). The effect was similar at all levels of these risk factors and there was no evidence of an interaction.

TABLE 3 Haematocrit and adjusted relative risk (RR) (95% confidence interval) of major ischaemic heart disease (IHD) events in men with and without pre-existing IHD

<table>
<thead>
<tr>
<th>Haematocrit level</th>
<th>No of men</th>
<th>No of IHD cases</th>
<th>Adjusted RRs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A</td>
</tr>
<tr>
<td>&lt;42</td>
<td>922</td>
<td>50 (44)</td>
<td>1-00</td>
</tr>
<tr>
<td>42-152</td>
<td>1202</td>
<td>47 (56)</td>
<td>1-00</td>
</tr>
<tr>
<td>44-152</td>
<td>1528</td>
<td>4-9 (71)</td>
<td>0-96</td>
</tr>
<tr>
<td>46-1030</td>
<td>1030</td>
<td>8-2 (80)</td>
<td>1-63</td>
</tr>
<tr>
<td>48-723</td>
<td>723</td>
<td>7-6 (52)</td>
<td>1-27</td>
</tr>
</tbody>
</table>

 ≥46-0% v rest p<0.0001 p=0.002 p=0.04 p=0.01 p=0.07 p=0.10

Relative risk 1-67 1-46 1-35 1-30 1-46 1-40 1-30 1-26

(A) Adjusted for age, social class, smoking, physical activity, body mass index, lung function, and diabetes.
(B) Adjusted in addition for blood cholesterol.
(C) Adjusted in addition for systolic blood pressure.

HAEMATOCRIT AND SERUM PROTEIN

It is well established that haematocrit is an important determinant of blood viscosity. Since circulatory protein is also a major determinant of blood viscosity, we examined whether total serum protein is related to haem-
haematocrit and the risk of IHD events. Haemato-
crit is significantly associated with total serum protein concentration ($r = 0.18$) and with its main components, albumin ($r = 0.13$) and globulin ($r = 0.19$). However, the total serum protein concentration showed no association with the risk of IHD events once age, smoking, blood pressure, blood cholesterol, and social class are taken into account. The relationship between haematocrit and risk of IHD is thus unaffected by adjustment for total serum protein concentration.

**Discussion**

In this study of middle-aged British men, a raised haematocrit ($\geq 46$) was associated with an increase in risk of major IHD events independent of age, social class, body weight, physical activity, lung function, and pre-existing IHD, diabetes and each of the other factors. Increased haematocrit was found to be significantly associated with raised blood cholesterol and for systolic blood pressure were at the highest levels of haematocrit ($\geq 140$ mmol/l). Although some of the excess risk was due to raised systolic blood pressure, this did not account for all the excess risk seen. This implies that the mechanism in the haematocrit-IHD relationship is either to some extent independent of blood lipids and blood pressure or that the process of adjustment does not take into account the imprecision of the measured risk factors.

**Other Studies**

Several studies have found the relationship between haematocrit and heart attacks to be dependent on blood cholesterol and systolic blood pressure. In these studies a linear relationship has been assumed and multiple regression analyses have been used, fitting haematocrit as a continuous variable and assessing the significance of the trend after adjustment. In the present study, haematocrit was raised only at levels of 46.0% and beyond with no further increase at higher levels after adjustment for the established coronary risk factors. Furthermore, men with low haematocrit had a slight increase in risk after adjustment for cholesterol and blood pressure compared with those within the range 42.0–45.9%. In one study, those with a low haematocrit have been shown to have a slight increase in risk of coronary heart disease mortality, so that assuming a linear relationship would flatten the trend, even though the risk might be significantly raised at higher levels of haematocrit. Nevertheless, the Puerto Rican Study found a significant positive association between haematocrit (fitted as a continuous variable) and risk of heart attacks even after adjustment for the established risk factors, and in the Stockholm Prospective Study, haemoglobin, which is highly correlated with haematocrit, was found to be significantly and independently associated with risk of myocardial infarction. A recent study which has used cut-off points has found a significant relationship between a raised haematocrit ($\geq 46.0\%$) and the risk of heart attacks even after adjustment for the coronary risk factors. Raised haematocrit was associated with a twofold increase in the risk of heart attacks compared with those...
with lower levels. The positive association between a raised haematocrit and IHD has also been observed in women. In a study of 1438 women aged 45–74, a haematocrit level over 45-0% was associated with an increased risk of IHD mortality even after adjustment for smoking. No data were available on blood cholesterol or blood pressure.9

BLOOD VISCOSITY

Although the mechanism for the role of haematocrit in the development of atherosclerosis is uncertain, there is growing speculation that its effect may be via blood viscosity.10 Haematocrit is the strongest determinant of whole blood viscosity.1 A linear increase in haematocrit produces an exponential increase in blood viscosity, thereby reducing blood flow particularly at sites of vascular damage and low shear rate. The exponential nature of this association may provide an explanation for the non-linear shape of the relationship between haematocrit and IHD events. The adverse effect of raised haematocrit (≥46%) within the normal reference range, as within the polycythemic range, may be mediated via a viscosity induced reduction in blood flow.

Plasma viscosity, although less important as a determinant of whole blood viscosity than haematocrit,1 may also make an important contribution to cardiovascular risk. Fibrinogen is an important determinant of plasma viscosity, particularly at low shear rates, and is an independent predictor of cardiovascular events.31 Cigarette smoking is the major environmental determinant of the fibrinogen level and about half of the IHD risk in cigarette smokers can be attributed to their higher fibrinogen level.32 It is also suggested that fibrinogen variations within the levels encountered in the general population may reflect the activity and instability of the atherosclerotic plaque.33 However, a recent report from the Caerphilly study suggests that plasma viscosity has an influence on IHD risk which is independent from that of fibrinogen, although the conclusion is dependent on the precise adjustment used.4 Fibrinogen was not measured in this study and thus the independent contributions of haematocrit, plasma viscosity, and fibrinogen concentration to the IHD risk need to be examined further in longitudinal studies with data on all these factors.

CONCLUSION

This study suggests that a raised haematocrit plays a role in the development of major IHD. There was no difference in the risk of IHD at haematocrit levels within the range 42.0–45.9 observed in population studies. At levels of 46-0% and beyond the risk of heart attacks increased. Some of the increased risk of IHD was associated with the established coronary risk factors but even after adjusting for these risk factors there still remained an independent effect of a raised haematocrit on the risk of major IHD events. This effect could be related to the implication with which the adjusted variables are measured, or it could be truly independent. The findings support the suggestion that blood rheology, of which the haematocrit is an important component, plays a part in the development of IHD.

The British Regional Heart Study is a British Heart Foundation Group and is also supported by the Department of Health and The Stroke Association. Haematocrit measurements were determined in the Department of Haematology, Queen Elizabeth Hospital, Birmingham, supported by the Department of Health. We thank Professor J Stuart for his valuable comments on the paper.

Ischaemic heart disease: association with haematocrit in the British Regional Heart Study.

G Wannamethee, A G Shaper and P H Whincup

*J Epidemiol Community Health* 1994 48: 112-118
doi: 10.1136/jech.48.2.112

Updated information and services can be found at:
http://jech.bmj.com/content/48/2/112

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/